Mississippi Cannabis Economic Impact — $139M in 2025

Last verified: May 2026

Tax Revenue Through Year-End 2025

Mississippi’s medical cannabis program produced the following measured revenue:

• FY 2023 (partial year): $11.2M retail sales / ~$0.78M sales tax / ~$0.5M excise.
• FY 2024: $75.3M retail / ~$5.3M sales tax / $7.5M excise + permit fees.
• FY 2025: $118.7M retail / ~$8.3M sales tax / $7.4M excise + permit fees.
• Calendar Year 2025: ~$139M retail / $9.0M sales tax / $2.18M excise alone.

Cumulative retail sales since launch crossed $300 million in early 2026, matching the projection cited by industry analysts in early 2025. Medical cannabis tax revenue flows to Mississippi’s general fund. Jackson and Tupelo levy local taxes on top of the state’s 7% sales tax.

Job Creation

Per the MMMA’s August 2025 industry presentation, the licensed medical cannabis industry in Mississippi supports approximately 2,500–3,500 direct jobs (cultivators, processors, dispensary staff, transporters, lab workers) and substantially more in adjacent services (legal, accounting, security, packaging, real estate).

Southern Sky Brands alone hired hundreds at its 70,000-sq-ft Canton facility. The industry is, however, beginning to consolidate — Crisler reported a 3.5% drop in license participation in 2025.

Market Size in National Context

A useful comparison: states with similar populations and recent medical cannabis launches.

• Mississippi: ~2.94M population / ~67,000 medical patients / ~$139M annual sales (2025).
• West Virginia: ~1.77M population / ~21,500 patients (2024) / ~$30M annual sales.
• Oklahoma: ~4.07M population / ~360,000 patients / ~$700M annual sales.

Oklahoma’s comparison is misleading — it operates one of the nation’s loosest medical programs, functioning as de facto recreational. West Virginia, with a similar conservative profile but roughly half Mississippi’s population, has under one-third the patient count. Mississippi’s program is, for a deeply conservative Southern state, performing well above expectations on patient enrollment and revenue.

Rural Economic Development

Cultivation facilities in Canton (Southern Sky), Brookhaven (multiple), Vicksburg, and other rural communities have brought $50,000–$80,000 manufacturing-grade jobs to areas where median household income often runs below $40,000. This is meaningful local impact in counties that have struggled with structural economic decline since the decline of textiles and the agricultural mechanization of the mid-20th century.

SB 2095 deliberately excluded medical cannabis establishments from Mississippi Development Authority financing programs (Health Care Industry Zone Act, Gulf Coast Restoration Fund, Economic Development Highway Act, etc.), so the rural economic-development case has had to be made entirely with private capital.

The Federal § 280E Tax Burden

Until federal cannabis rescheduling completes, Mississippi cannabis businesses face the IRC § 280E burden: federal tax law disallows ordinary business deductions (labor, rent, marketing) for businesses "trafficking" in Schedule I or II controlled substances. Effectively, cannabis operators pay federal tax on gross profit rather than net profit, which is a substantial cash drag on the industry.

Industry estimates put the § 280E impact at 20–30% of operating cash flow for typical Mississippi cannabis operators — a meaningful constraint on reinvestment, hiring, and price competitiveness.

The Trump Executive Order 14370 Rescheduling Tailwind

On December 18, 2025, President Donald Trump signed Executive Order 14370, "Increasing Medical Marijuana and Cannabidiol Research," which directed the U.S. Attorney General to "take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA" (Sec. 2(a)).

As of April 2026, the rescheduling rule had not been finalized. If completed, the change would:

• Relieve the IRC § 280E tax burden on Mississippi cannabis businesses.
• Potentially free capital for product development, lower prices for patients, and easier banking.
• Enable substantially expanded clinical research at Ole Miss (NCNPR, NCCRE) and UMMC.
• Likely reduce some of the federal-employer drug-testing pressure (though not eliminate it).

Mississippi industry leaders, including the MMMA’s Crisler, expressed cautious optimism in early 2026.

Watch Indicators for 2026

Several measurable indicators will signal the trajectory of the Mississippi cannabis economy through 2026:

• License participation — if MSDH issues fewer than 24 net new licenses in 2026 (the current ~2–3/month pace), the consolidation trend is accelerating.
• Patient growth — whether the 41.5% 2025 enrollment growth rate sustains, slows, or accelerates.
• Federal rescheduling completion — the binding regulatory variable for industry economics.
• HB 895 / HB 1152 override votes — whether the legislature takes up the vetoed bills before adjournment or in 2027.
• Local opt-out reversals — how many additional cities follow Lauderdale County’s example.
• SCR 518 progress — ballot-initiative restoration as the structural prerequisite to recreational reform.

The Banking Layer

Mississippi cannabis businesses have limited banking access. Federally-chartered banks generally decline cannabis-business accounts due to federal Schedule I status. Mississippi-chartered community banks and credit unions occasionally provide services, but at premium fees and with limited transaction infrastructure. The SAFER Banking Act (proposed federal legislation that would protect financial institutions serving cannabis businesses) has not passed Congress as of April 2026 — though federal rescheduling to Schedule III, if completed, would substantially reduce the banking friction even without SAFER.